AEterna Zentaris (AEterna Zentaris) 3-Year Revenue Growth Rate : -24.10% (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is AEterna Zentaris 3-Year Revenue Growth Rate?

AEterna Zentaris's Revenue per Share for the three months ended in Dec. 2023 was $0.03.

During the past 12 months, AEterna Zentaris's average Revenue per Share Growth Rate was -21.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was -24.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was -40.30% per year. During the past 10 years, the average Revenue per Share Growth Rate was -24.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of AEterna Zentaris was 129.60% per year. The lowest was -91.20% per year. And the median was -18.20% per year.

Competitive Comparison of AEterna Zentaris's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, AEterna Zentaris's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEterna Zentaris's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's 3-Year Revenue Growth Rate falls into.

AEterna Zentaris 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

AEterna Zentaris (NAS:AEZS) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

AEterna Zentaris 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (AEterna Zentaris) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

ET8:Germany ET8:Germany AEZS:Canada

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.